β-CIT的~(131)I标记及其初步临床应用

β-CIT Labeled With ~(131)Iand Its Preliminary Clinical Practice

  • 摘要: 用过氧乙酸法进行了β-CIT的131I标记,并用标记物对4例正常对照、8例帕金森氏病(PD)患者、3例帕金森氏综合征(PS)患者进行显像,计算纹状体与小脑的放射性摄取比(特异性摄取)及纹状体131I-β-CIT摄取的非对称指数AI。结果显示:131I-β-CIT放化纯度达(97.6±0.3)%,室温下放置4h以及分别与水、人新鲜血清孵育4h后,其放化纯度仍均>95%;纹状体能特异摄取131I-β-CIT,与正常对照组及PS组相比,PD患者双侧纹状体摄取的放射性明显降低(P<0.01),且症状对侧降低更明显;PS患者与正常对照组相比,其纹状体摄取无明显差异(P>0.05)。直线回归分析显示,PD患者症状的严重程度与纹状体特异摄取131I-β-CIT下降密切相关。提示131I-β-CIT多巴胺转运蛋白显像可作为PD诊断、鉴别诊断和病情严重程度的客观指标。

     

    Abstract: βCIT is labled with 131I by the peracetic acid method. 4 normal controls, 8 patients with PD and 3 patients with PS are studied by 131IβCIT SPECT imaging. Striatal specific uptake of 131IβCIT is calculated by the radioactivity ratio of striatal to cerebellar. The results show that the radiochemical purity of 131IβCIT is (97.6±0.3)%.131IβCIT remains stable for at least 4 h after incubated with waters and serum respectively. The striatal specific uptake of 131IβCIT in normal controls, PD and PS patients are (4.39±0.14)%,(2.95±0.68)% and (3.96±0.52)% at 4 h and (6.60±0.06)%,(3.85±0.71)% and (6.14±0.08)% at 20 h after administration. There is a significant reduction of striatial tracer uptake in PD patients compared to the controls and PS patients. Striatal specific uptake in contralateral to the clinical symptom side is more pronounced reduced than the ipsilateral side in PD patients. 131IβCIT uptake in PD patients is correlated with disease severity. These results suggest that 131IβCIT can be used for the diagnosis of Parkinsion's disease.

     

/

返回文章
返回